Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin

Ingrid Tein, Orly Elpeleg, Bruria Ben-Zeev, Stanley H. Korman, Alexander Lossos, Dorit Lev, Tally Lerman-Sagie, Esther Leshinsky-Silver, Jerry Vockley, Gerard T. Berry, Anne Marie Lamhonwah, Dietrich Matern, Charles R. Roe, Niels Gregersen

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

We report 10 children (7 male, 3 female), 3 homozygous for c.319C>T mutation and 7 heterozygous for c.319C>T on one allele and c.625G>A variant on the other in the short-chain acyl-CoA dehydrogenase (SCAD) gene (ACADS). All were of Ashkenazi Jewish origin in which group we found a c.319C>T heterozygote frequency of 1:15 suggesting the presence of a founder mutation or selective advantage. Phenotype was variable with onset from birth to early childhood. Features included hypotonia (8/10), developmental delay (8/10), myopathy (4/10) with multicore changes in two and lipid storage in one, facial weakness (3/10), lethargy (5/10), feeding difficulties (4/10) and congenital abnormalities (3/7). One female with multiminicore myopathy had progressive external ophthalmoplegia, ptosis and cardiomyopathy with pneumonia and respiratory failure. Two brothers presented with psychosis, pyramidal signs, and multifocal white matter abnormalities on MRI brain suggesting additional genetic factors. Two other infants also had white matter changes. Elevated butyrylcarnitine (4/8), ethylmalonic aciduria (9/9), methylsuccinic aciduria (6/7), decreased butyrate oxidation in lymphoblasts (2/4) and decreased SCAD activity in fibroblasts or muscle (3/3) were shown. Expression studies of c.319C>T in mouse liver mitochondria showed it to be inactivating. c.625G>A is a common variant in ACADS that may confer disease susceptibility. Five healthy parents were heterozygous for c.319C>T and c.625G>A, suggesting reduced penetrance or broad clinical spectrum. We conclude that the c.319C>T mutation can lead to wide clinical and biochemical phenotypic variability, suggesting a complex multifactorial/polygenic condition. This should be screened for in individuals with multicore myopathy, particularly among the Ashkenazim.

Original languageEnglish (US)
Pages (from-to)179-189
Number of pages11
JournalMolecular Genetics and Metabolism
Volume93
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Butyryl-CoA Dehydrogenase
Genes
Acyl-CoA Dehydrogenase
Mutation
Mitochondria
Butyrates
Fibroblasts
Chronic Progressive External Ophthalmoplegia
Liver
Magnetic resonance imaging
Muscle
Brain
Lethargy
Muscle Hypotonia
Penetrance
Liver Mitochondrion
Disease Susceptibility
Muscular Diseases
Heterozygote
Cardiomyopathies

Keywords

  • Ashkenazi
  • Developmental delay
  • Ethylmalonic aciduria
  • Fatty acid oxidation
  • Multicore myopathy
  • Myopathy
  • Short-chain acyl-CoA dehydrogenase deficiency

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Cite this

Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin. / Tein, Ingrid; Elpeleg, Orly; Ben-Zeev, Bruria; Korman, Stanley H.; Lossos, Alexander; Lev, Dorit; Lerman-Sagie, Tally; Leshinsky-Silver, Esther; Vockley, Jerry; Berry, Gerard T.; Lamhonwah, Anne Marie; Matern, Dietrich; Roe, Charles R.; Gregersen, Niels.

In: Molecular Genetics and Metabolism, Vol. 93, No. 2, 02.2008, p. 179-189.

Research output: Contribution to journalArticle

Tein, I, Elpeleg, O, Ben-Zeev, B, Korman, SH, Lossos, A, Lev, D, Lerman-Sagie, T, Leshinsky-Silver, E, Vockley, J, Berry, GT, Lamhonwah, AM, Matern, D, Roe, CR & Gregersen, N 2008, 'Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin', Molecular Genetics and Metabolism, vol. 93, no. 2, pp. 179-189. https://doi.org/10.1016/j.ymgme.2007.09.021
Tein, Ingrid ; Elpeleg, Orly ; Ben-Zeev, Bruria ; Korman, Stanley H. ; Lossos, Alexander ; Lev, Dorit ; Lerman-Sagie, Tally ; Leshinsky-Silver, Esther ; Vockley, Jerry ; Berry, Gerard T. ; Lamhonwah, Anne Marie ; Matern, Dietrich ; Roe, Charles R. ; Gregersen, Niels. / Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin. In: Molecular Genetics and Metabolism. 2008 ; Vol. 93, No. 2. pp. 179-189.
@article{962edd0aeddf4692bd58b5674b7a8336,
title = "Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin",
abstract = "We report 10 children (7 male, 3 female), 3 homozygous for c.319C>T mutation and 7 heterozygous for c.319C>T on one allele and c.625G>A variant on the other in the short-chain acyl-CoA dehydrogenase (SCAD) gene (ACADS). All were of Ashkenazi Jewish origin in which group we found a c.319C>T heterozygote frequency of 1:15 suggesting the presence of a founder mutation or selective advantage. Phenotype was variable with onset from birth to early childhood. Features included hypotonia (8/10), developmental delay (8/10), myopathy (4/10) with multicore changes in two and lipid storage in one, facial weakness (3/10), lethargy (5/10), feeding difficulties (4/10) and congenital abnormalities (3/7). One female with multiminicore myopathy had progressive external ophthalmoplegia, ptosis and cardiomyopathy with pneumonia and respiratory failure. Two brothers presented with psychosis, pyramidal signs, and multifocal white matter abnormalities on MRI brain suggesting additional genetic factors. Two other infants also had white matter changes. Elevated butyrylcarnitine (4/8), ethylmalonic aciduria (9/9), methylsuccinic aciduria (6/7), decreased butyrate oxidation in lymphoblasts (2/4) and decreased SCAD activity in fibroblasts or muscle (3/3) were shown. Expression studies of c.319C>T in mouse liver mitochondria showed it to be inactivating. c.625G>A is a common variant in ACADS that may confer disease susceptibility. Five healthy parents were heterozygous for c.319C>T and c.625G>A, suggesting reduced penetrance or broad clinical spectrum. We conclude that the c.319C>T mutation can lead to wide clinical and biochemical phenotypic variability, suggesting a complex multifactorial/polygenic condition. This should be screened for in individuals with multicore myopathy, particularly among the Ashkenazim.",
keywords = "Ashkenazi, Developmental delay, Ethylmalonic aciduria, Fatty acid oxidation, Multicore myopathy, Myopathy, Short-chain acyl-CoA dehydrogenase deficiency",
author = "Ingrid Tein and Orly Elpeleg and Bruria Ben-Zeev and Korman, {Stanley H.} and Alexander Lossos and Dorit Lev and Tally Lerman-Sagie and Esther Leshinsky-Silver and Jerry Vockley and Berry, {Gerard T.} and Lamhonwah, {Anne Marie} and Dietrich Matern and Roe, {Charles R.} and Niels Gregersen",
year = "2008",
month = "2",
doi = "10.1016/j.ymgme.2007.09.021",
language = "English (US)",
volume = "93",
pages = "179--189",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin

AU - Tein, Ingrid

AU - Elpeleg, Orly

AU - Ben-Zeev, Bruria

AU - Korman, Stanley H.

AU - Lossos, Alexander

AU - Lev, Dorit

AU - Lerman-Sagie, Tally

AU - Leshinsky-Silver, Esther

AU - Vockley, Jerry

AU - Berry, Gerard T.

AU - Lamhonwah, Anne Marie

AU - Matern, Dietrich

AU - Roe, Charles R.

AU - Gregersen, Niels

PY - 2008/2

Y1 - 2008/2

N2 - We report 10 children (7 male, 3 female), 3 homozygous for c.319C>T mutation and 7 heterozygous for c.319C>T on one allele and c.625G>A variant on the other in the short-chain acyl-CoA dehydrogenase (SCAD) gene (ACADS). All were of Ashkenazi Jewish origin in which group we found a c.319C>T heterozygote frequency of 1:15 suggesting the presence of a founder mutation or selective advantage. Phenotype was variable with onset from birth to early childhood. Features included hypotonia (8/10), developmental delay (8/10), myopathy (4/10) with multicore changes in two and lipid storage in one, facial weakness (3/10), lethargy (5/10), feeding difficulties (4/10) and congenital abnormalities (3/7). One female with multiminicore myopathy had progressive external ophthalmoplegia, ptosis and cardiomyopathy with pneumonia and respiratory failure. Two brothers presented with psychosis, pyramidal signs, and multifocal white matter abnormalities on MRI brain suggesting additional genetic factors. Two other infants also had white matter changes. Elevated butyrylcarnitine (4/8), ethylmalonic aciduria (9/9), methylsuccinic aciduria (6/7), decreased butyrate oxidation in lymphoblasts (2/4) and decreased SCAD activity in fibroblasts or muscle (3/3) were shown. Expression studies of c.319C>T in mouse liver mitochondria showed it to be inactivating. c.625G>A is a common variant in ACADS that may confer disease susceptibility. Five healthy parents were heterozygous for c.319C>T and c.625G>A, suggesting reduced penetrance or broad clinical spectrum. We conclude that the c.319C>T mutation can lead to wide clinical and biochemical phenotypic variability, suggesting a complex multifactorial/polygenic condition. This should be screened for in individuals with multicore myopathy, particularly among the Ashkenazim.

AB - We report 10 children (7 male, 3 female), 3 homozygous for c.319C>T mutation and 7 heterozygous for c.319C>T on one allele and c.625G>A variant on the other in the short-chain acyl-CoA dehydrogenase (SCAD) gene (ACADS). All were of Ashkenazi Jewish origin in which group we found a c.319C>T heterozygote frequency of 1:15 suggesting the presence of a founder mutation or selective advantage. Phenotype was variable with onset from birth to early childhood. Features included hypotonia (8/10), developmental delay (8/10), myopathy (4/10) with multicore changes in two and lipid storage in one, facial weakness (3/10), lethargy (5/10), feeding difficulties (4/10) and congenital abnormalities (3/7). One female with multiminicore myopathy had progressive external ophthalmoplegia, ptosis and cardiomyopathy with pneumonia and respiratory failure. Two brothers presented with psychosis, pyramidal signs, and multifocal white matter abnormalities on MRI brain suggesting additional genetic factors. Two other infants also had white matter changes. Elevated butyrylcarnitine (4/8), ethylmalonic aciduria (9/9), methylsuccinic aciduria (6/7), decreased butyrate oxidation in lymphoblasts (2/4) and decreased SCAD activity in fibroblasts or muscle (3/3) were shown. Expression studies of c.319C>T in mouse liver mitochondria showed it to be inactivating. c.625G>A is a common variant in ACADS that may confer disease susceptibility. Five healthy parents were heterozygous for c.319C>T and c.625G>A, suggesting reduced penetrance or broad clinical spectrum. We conclude that the c.319C>T mutation can lead to wide clinical and biochemical phenotypic variability, suggesting a complex multifactorial/polygenic condition. This should be screened for in individuals with multicore myopathy, particularly among the Ashkenazim.

KW - Ashkenazi

KW - Developmental delay

KW - Ethylmalonic aciduria

KW - Fatty acid oxidation

KW - Multicore myopathy

KW - Myopathy

KW - Short-chain acyl-CoA dehydrogenase deficiency

UR - http://www.scopus.com/inward/record.url?scp=38049177259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049177259&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2007.09.021

DO - 10.1016/j.ymgme.2007.09.021

M3 - Article

C2 - 18054510

AN - SCOPUS:38049177259

VL - 93

SP - 179

EP - 189

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 2

ER -